Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3]
- RabMAb
- What is this?
Be the first to review this product! Submit a review
|
(0 Publication)
Rabbit Monoclonal Amyloid-beta precursor protein antibody. Suitable for WB, I-ELISA, Dot and reacts with Human, Synthetic peptide samples.
View Alternative Names
A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II
- I-ELISA
Supplier Data
Indirect ELISA - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)
Indirect ELISA antibody dose-response curve using ab264034 with antigen at 1000 ng/ml
- WB
Supplier Data
Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)
Blocking and diluting buffer and concentration was 5% NFDM/TBST.
Lanes 1 - 2:
Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034) at 1/1000 dilution
Lanes 1 - 2:
Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab290645) at 1/1000 dilution
Lane 1:
beta Amyloid pE3-42 (aa674-713) peptide 100ng
Lane 2:
beta Amyloid 1-42 (aa672-713) peptide 100ng
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/1000000 dilution
false
Exposure time: 3s
- Dot
Supplier Data
Dot Blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)
Dot blot analysis of pyroglutamate beta amyloid using ab264034 at 1/2000 dilution, followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100,000 dilution.
Blocking and diluting buffer and concentration was 5% NFDM/TBST.
Lane 1 : beta Amyloid pE3-42 (aa674-713) peptide
Lane 2 : beta Amyloid 1-42 (aa672-713) peptide
Exposure time : 3 minutes.
Related conjugates and formulations (1)
-
Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Pyroglutamate beta amyloid affects neuronal function by increasing the aggregation propensity of beta amyloid. It enhances the toxic effects on synapses and neurons disrupting communication and leading to synaptic dysfunction. Pyroglutamate-modified amyloid beta is a component of the amyloid plaque complex which includes other amyloid peptides and metal ions. The presence of pGlu-Aβ in these plaques enhances their stability and neurotoxicity accelerating neuronal degradation and loss of cognitive functions.
Pathways
Modified pyroglutamate beta amyloid involves itself in amyloidogenic pathways that include processes such as the beta-secretase and gamma-secretase pathways. These pathways lead to production and modification of amyloid beta peptide initiating plaque formation in the brain. The interaction of pyroglutamate beta amyloid with tau protein is significant as the aggregation of these proteins advances neurodegeneration. Tau proteins become hyperphosphorylated in response disrupting cellular transport and further promoting Alzheimer's disease progression.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com